In this episode, we sit down with world-renowned futurist Bruce McCabe to cut through the hype of large language models like ChatGPT and explore the "stunningly optimistic" reality of Specialist (Narrow) AI.

Bruce shares insights from his global travels to research labs, explaining why the future of medicine isn’t one "God-like" AI, but rather a "hive mind" of tens of thousands of highly trained, testable, and trustworthy specialist systems. From early tumor detection in radiology to the revolutionary protein-folding predictions of AlphaFold, we discuss how AI is incrementally building toward a more precise and efficient healthcare system.

Key Discussion Points:

• Moving Beyond the Hype: Why the current "AI correction" is only about large language models, and why narrow AI is actually underhyped.
• The Power of Specialist Systems: How AI trained on specific datasets (like 100,000 X-rays) achieves higher reliability and lower false-positive rates than general models.
• The "Hive Mind" Concept: A future where thousands of specialist AIs interact to provide comprehensive patient care while maintaining data anonymity.
• Trust and Testing: How we measure the trustworthiness of AI in dermatology and diagnostics through historical clinical data.
• Edge Computing & Privacy: Solving the patient privacy dilemma by using Small Language Models (SLMs) that live on local hospital servers rather than the cloud.
• The Next Frontier: The role of AI in material science, drug construction, and programmable medicines like CAR T-cell therapy.

About Our Guest:

Bruce McCabe is a futurist, speaker, and author who spends half the year visiting scientists and innovators around the world to understand how technology will shape our future. You can find his research and book him for speaking engagements at BruceMcCabe.com.

Support the show

www.kulkarnilawfirm.com

In this episode of DarshanTalks, host and attorney-pharmacist Darshan Kulkarni deconstructs the legal "scorched-earth" offensive currently reshaping the weight loss drug industry. Following the February 2026 announcement that the GLP-1 shortage is officially resolved, the "Golden Age" for compounders has vanished overnight, leaving companies like Hims & Hers in the crosshairs of both the FDA and Novo Nordisk.

Darshan takes us from the tragic "ghost" of the 2012 NECC fungal meningitis outbreak to the modern-day "Compounding Wild West." We explore the crucial differences between Section 503A and 503B pharmacies and why adding Vitamin B12 to a patented molecule isn't the "customization" compounders claim it is.
Key topics include:

• The NECC Legacy: How a 2012 tragedy created the Drug Quality and Security Act (DQSA) and why the FDA is using it to end the mass-marketing of copycat drugs.
• The Science of the "Bluff": Why "not adulterated" does not mean "safe and effective" under the FD&C Act.
• Novo Nordisk vs. Hims & Hers: The billion-dollar patent battle and why the DOJ is now getting involved.
• The Shortage Shield: What happens to telehealth platforms the moment the FDA "Shortage" flag disappears.

Don't let your healthcare be decided by an Instagram ad. Understand the intersection of biochemistry and federal law to protect your health and your practice.

Support the show

www.kulkarnilawfirm.com

In this episode, I sit down with FDA compliance attorney Heather Butos to unpack two topics most cosmetic pros ignore until it’s too late: INCI (ingredient) names and MOCRA (the new cosmetic law).

We talk about how ingredient naming is not just labeling, it’s a strategic business decision that can make or break product marketing. Heather breaks down how the Personal Care Products Council influences naming conventions, why companies struggle to sell ingredients when they can’t describe them well, and what’s actually allowed under FDA rules.

We also dive into the Modernization of Cosmetics Regulation Act (MOCRA). We discuss what’s already in effect, what’s still vague, and why this transition period is both confusing and critical. Along the way we share real-world GMP audit stories, how COVID shaped compliance, and why walking the factory floor gives better regulatory insight than just reading guidance documents.

This is not your typical cosmetic compliance talk. If you make or sell cosmetics, personal care products, or ingredients, pay attention.

Show Notes (Bulleted)

• What are INCI names and why they exist
• The Personal Care Products Council and how INCI naming works
• How ingredient naming crosses into marketing strategy
• Real-world examples of label creativity and regulatory risk
• Making sense of MOCRA — what’s live, what’s stuck
• Why registration, adverse event reporting, and safety substantiation matter now
• What we still don’t know about cosmetic GMP enforcement
• GMP audits vs desk compliance — why experience matters
• U.S. vs EU regulatory contrast (quick take)
• Tips for staying compliant while FDA rules evolve

What You’ll Learn

• How to think about ingredient names as part of your product strategy
• What’s actually required vs what’s still vague in cosmetic regulation
• How the naming process works with industry groups
• How MOCRA changes the compliance landscape
• Real compliance lessons from factory audits

Resources Mentioned

• Personal Care Products Council
• MOCRA (Modernization of Cosmetics Regulation Act)
• Cosmetic registration and listing
• Adverse event reporting basics

Who This Is For

• Cosmetic brand owners and founders
• Ingredient suppliers and formulators
• Regulatory affairs professionals
• Legal and compliance teams
• Anyone confused by cosmetic labeling rules

Recommended Chapters (Timestamped)

Use these in Buzzsprout chapter markers:

0:00 — Intro
1:30 — What INCI ingredient names are
3:30 — How ingredient naming affects marketing
7:00 — Creative labeling and regulatory limits
10:00 — GMP audits and manufacturing reality
13:50 — What MOCRA is
16:30 — Which MOCRA rules are live
19:00 — What’s still vague or coming
21:30 — EU vs US differences
24:00 — Tips for compliance
27:00 — Outro

Support the show

www.kulkarnilawfirm.com